ValiRx walks away from Stingray Bio licence option
ValiRx (AIM:VAL) completed an in-silico evaluation of Stingray Bio's assets and concluded the technology requires further optimisation before it can reach the candidate stage, leading the company to decline its option to licence. The decision removes a near-term pipeline catalyst and sent the shares down 7.69% to 0.18p.
Verici Dx PTRA test modelled to save $191m in US transplants
Verici Dx (AIM:VRCI) published a health economic analysis in a peer-reviewed journal estimating that its Pre-Transplant Risk Assessment test could deliver more than $191m in healthcare savings across the US standard-risk kidney transplant population. The study provides independent, published validation of the commercial case for PTRA at a time when the company is building its US market strategy, and the shares responded with a gain of 4.71% to 0.445p.
Inspiration Healthcare exits Micrel UK infusion distribution
Inspiration Healthcare Group (AIM:IHC) will hand back exclusive UK distribution rights for Micrel ambulatory infusion pumps and consumables to the manufacturer, a line that generated £9.7m in revenue at an approximate 25% contribution margin in the year to 31 January. The exit strips out a meaningful revenue stream and the market marked the shares down 7.12% to 26.1p on the news.
Hammerson prices €350m bond and extends credit facilities
Hammerson (LSE:HMSO) priced a €350m five-year bond as part of the refinancing of its €700m 2027 bond, and simultaneously renewed and extended its revolving credit facilities, lifting committed undrawn facilities to £613m. The company maintained its full-year 2026 EPRA earnings guidance at approximately £120m, and the shares edged up 0.53% to 341.2p.
